Q3 EPS Estimate for Arcus Biosciences Reduced by Analyst

Key Points

• HC Wainwright has reduced its Q3 2025 earnings per share (EPS) estimate for Arcus Biosciences from ($1.24) to ($1.32), reflecting a more pessimistic outlook for the company.
• Several analysts have adjusted their target prices for Arcus Biosciences, with Morgan Stanley lowering it from $24.00 to $22.00 while Barclays significantly cut their price target from $29.00 to $14.00.
• Arcus Biosciences reported a revenue increase of 310.3% year-over-year, with Q2 earnings at ($1.11) EPS, surpassing consensus estimates of ($1.14) EPS by $0.03.

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at HC Wainwright cut their Q3 2025 earnings per share estimates for Arcus Biosciences in a research note issued on Thursday, August 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($1.32) per share for the quarter, down from their previous estimate of ($1.24). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences' Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($3.83) EPS, FY2026 earnings at ($4.13) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($3.04) EPS and FY2029 earnings at ($1.87) EPS.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. The firm had revenue of $160.00 million during the quarter, compared to analyst estimates of $32.86 million. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%. The business's quarterly revenue was up 310.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.02) earnings per share.

Several other equities analysts have also commented on the company. Wells Fargo & Company dropped their target price on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Barclays dropped their price target on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research note on Wednesday, April 23rd. Wedbush restated an "outperform" rating and set a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Morgan Stanley dropped their price target on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Finally, The Goldman Sachs Group dropped their price target on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Arcus Biosciences currently has an average rating of "Moderate Buy" and an average target price of $21.14.

Arcus Biosciences Trading Down 1.8%

Arcus Biosciences stock traded down $0.18 during trading on Monday, hitting $9.88. The company's stock had a trading volume of 251,334 shares, compared to its average volume of 1,031,702. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -3.11 and a beta of 0.89. The stock's fifty day moving average is $9.15 and its 200 day moving average is $9.39. Arcus Biosciences has a 1-year low of $6.50 and a 1-year high of $18.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50.

Institutional Investors Weigh In On Arcus Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Arcus Biosciences by 2.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock worth $506,000 after buying an additional 833 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Arcus Biosciences by 8.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company's stock worth $142,000 after buying an additional 1,294 shares during the period. Parallel Advisors LLC boosted its position in shares of Arcus Biosciences by 1.6% in the second quarter. Parallel Advisors LLC now owns 88,007 shares of the company's stock worth $716,000 after buying an additional 1,422 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock worth $57,000 after buying an additional 1,796 shares during the period. Finally, Maryland State Retirement & Pension System boosted its position in shares of Arcus Biosciences by 10.9% in the first quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company's stock worth $159,000 after buying an additional 1,986 shares during the period. Hedge funds and other institutional investors own 92.89% of the company's stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.